Implantica AG’s Annual General Meeting Set for June 2026 with Critical Agenda Items

Annual General Meeting of Implantica AG

Implantica AG, a prominent name in medtech innovation, has announced its upcoming Annual General Meeting (AGM) set to take place on June 10, 2026. The event will be hosted at the Hotel Kommod in Ruggell, Liechtenstein, inviting all depository receipt holders to attend and participate in pivotal organizational decisions that will shape the company’s future.

Participation Requirements

To attend the AGM, participants must ensure their name is registered in the Swedish Depository Receipt (SDR) registry maintained by Euroclear Sweden by May 26, 2026. Attendees must then confirm their intention to participate by June 1, 2026, either via email or postal mail, providing details such as their name, personal identification details, and contact information. For those unable to attend in person, postal votes can be submitted following the outlined procedures.

This AGM serves as a platform to engage actively with critical issues and resolutions including the financial performance reports and board elections that directly impact shareholder interests.

Agenda Highlights

The agenda for the AGM includes several key items:

1. Opening and Chair Appointment: The meeting will commence with the appointment of a Chair, followed by the preparation and approval of the voting list.
2. Financial Statements: Participants will review and approve the statutory annual financial statements and consolidated financial results, providing insight into the company’s performance over the past fiscal year.
3. Appropriation of Retained Earnings: A crucial proposal to carry forward a net loss of CHF 1,482,311 from 2025, with a resolution not to distribute dividends, is on the agenda. This decision reflects the company’s strategy and financial prudence in turbulent market conditions.
4. Discharge of Directors and Executives: Shareholders will deliberate on granting discharge to the Board of Directors, Executive Management, and auditors for the previous financial year, a common procedure that signifies approval of their actions and decisions.
5. Approval of Remuneration: The meeting will also discuss the remuneration packages for the Board and Executive Management, totaling TEUR 192 and TEUR 2,016 respectively, confirming their compensation aligned with performance metrics.

Board Elections

Another significant aspect of this AGM involves the election of board members and integral committee positions. The Board of Directors proposes to re-elect its current members, including Liselott Kilaas as Chairman and Johan Bojs as Vice-Chairman, ensuring continuity in leadership and strategy execution.

Operational Updates and Future Vision

In addition to these administrative tasks, the CEO will address attendees, providing an overview of the company's strategic direction and operational updates. Notably, Implantica focuses on the innovative RefluxStop® device which is designed to address gastroesophageal reflux disease (GERD) more effectively compared to traditional methods.

Further, attendees will have the opportunity to inquire about the company’s performance and strategic initiatives, fostering an inclusive environment where shareholders can voice their concerns and expectations.

As the AGM approaches, Implantica is committed to keeping its shareholders informed. All relevant documents, including proposals and financial statements for the preceding year, will be accessible at the company’s office and via its official website three weeks prior to the meeting. Minutes from the AGM will be published on July 10, 2026, ensuring transparency and accountability.

Implantica remains steadfast in its mission to improve patient health outcomes through innovative medical technologies. Stakeholders are encouraged to participate actively in this significant occasion that will set the course for the company’s future operations and growth.